All In Biotech

Drug Trial Radar · NCT05015608

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Nov 22, 2021

Primary completion

Aug 22, 2025

Study completion Aug 22, 2025

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Aug 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Savolitinib + OsimertinibDrug

    Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

  • Pemetrexed + Cisplatin /CarboplatinDrug

    Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 5 months after the last patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.